A new paper released today in the Journal of Clinical Oncology finds that while incorporating pharmacogenomic (PGx) testing into cancer care can help improve patient outcomes, barriers to PGx testing, discovery, and implementation are impacting its adoption and creating disparities that impact diverse populations.
Dr. Christina Annunziata, the Senior Vice President of Extramural Discovery Science at the American Cancer Society, testified today before the House Committee on Energy and Commerce’s Subcommittee on Health in support of the Screening for Communities to Receive Early and Equitable Needed Services (SCREENS) for Cancer Act and the Women and Lung Research and Preventive Services Act.
Protecting free preventive cancer screenings and reducing the burden of medical debt are the top issues of concern for cancer patients and survivors today, according to a new survey by the American Cancer Society Cancer Action Network (ACS CAN) that asked participants to select their leading policy priorities for the year.
Today, the American Cancer Society Cancer Action Network (ACS CAN) issued a letter to the National Institutes of Standards and Technology (NIST) commenting on the utilization of march-in rights (MIR) to lower prescription drug costs following the release of new guidance by the administration on its application.
WASHINGTON, D.C. – Today, the American Cancer Society Cancer Action Network (ACS CAN) was joined by 20 other organizations in proposing the Health and Human Services Office of Inspector General adopt a new regulatory safe harbor from the Anti-kickback Statute that would allow cli
On the two-year anniversary of the reignited Cancer Moonshot, the American Cancer Society Cancer Action Network (ACS CAN) is calling on the White House and Congress to reinforce their commitment to end cancer as we know it by taking key steps to prioritize cancer prevention and research.
Our 25 organizations, representing patients with serious health conditions and providers who care for them, urge the Supreme Court to reverse the Fifth Circuit’s decision in Alliance for Hippocratic Medicine et al. v FDA et al. because it threatens patients’ and providers’ ability to rely on Food and Drug Administration (FDA) decisions about drug safety.
The American Cancer Society Cancer Action Network (ACS CAN) released a new report today, Cancer in Medicare: An American Cancer Society Cancer Action Network Chartbook, to illustrate how the Medicare program serves patients across the cancer continuum as well as specific public policy recommendations to improve and strengthen the program. Given an individual’s cancer risk increases with age, Medicare plays a key role in reducing suffering and death from cancer.
Yesterday, the U.S. Court of Appeals for the Second Circuit issued a decision in the case of Haller v. Health and Human Services (HHS) upholding the U.S. District Court’s ruling preserving the provisions of the No Surprises Act (NSA) that prohibit patients from receiving surprise bills for unexpected out-of-network costs. However, the case was remanded back to the lower court for reconsideration of the issue of payments between providers and insurers.
Today, the Supreme Court of the United States will hear oral arguments in the case of Loper Bright Enterprises v. Raimondo and its companion case, Relentless v. Dept. of Commerce. The cases put in question the “Chevron deference” that protects the legal stability of public health programs like Medicare and Medicaid that benefit nearly half of the U.S. population by ensuring that laws passed by Congress can continue to be interpreted and implemented by expert federal agencies such as the Centers for Medicare and Medicaid Services (CMS).